Categories: Bulk Drug

AstraZeneca bags another cancer drug deal, this time with Inovio

London, August 2015
AstraZeneca has clinched its third deal in less than a week to bolster its strategically important cancer drug pipeline by signing up rights to an experimental immune system-boosting medicine from Inovio Pharmaceuticals.

Inovio will get $27.5 million upfront and potential future payments of up to $700 million, depending on the success of its INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18.

AstraZeneca said on Monday its MedImmune biotech unit would study INO-3112 in combination with other immunotherapy drugs.

INO-3112, which is in Phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are able to destroy HPV 16- and 18-driven tumors. The two HPV types are responsible for more than 70 percent of cervical cancer.

The deal follows other recent immuno-oncology tie-ups by AstraZeneca with Sosei subsidiary Heptares and Mirati. Reuters

The Pharma Times News Bureau

Recent Posts

8 Ways Insomnia Affects Skin Health & How To Avoid It

By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…

1 day ago

Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and Treatment

Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…

1 day ago

Healthcare Startups to Watch Out for in 2025

New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…

2 days ago

DKMS’s First Global Impact Report of 2023 Serves as New Ray of Hope for Blood Cancer Patients Worldwide

National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…

2 days ago

Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat

Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…

3 days ago

Pioneers in Senior Care, Antara, Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…

3 days ago